MAM 06301

Drug Profile

MAM 06301

Alternative Names: Beta-aescin - Marinomed Biotechnologie; Beta-escin - Marinomed Biotechnologie; MAM-06.301

Latest Information Update: 10 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Marinomed Biotechnologie
  • Class Antiallergics
  • Mechanism of Action Nitric oxide modulators; Prostaglandin F2alpha receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Allergic asthma; Allergic contact dermatitis
  • No development reported Hypersensitivity

Most Recent Events

  • 10 Sep 2015 Preclinical development is ongoing in Austria
  • 10 Sep 2015 No recent reports on development identified - Phase-II for Allergic contact dermatitis in Germany (Topical)
  • 10 Sep 2015 No recent reports on development identified - Phase-II for Hypersensitivity in Germany (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top